Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 2/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.30 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5632668 | 0.81 | ESR1 (0.39) | KDM4EALDH1A1USP2CYP1A2GLA | |
| SCHEMBL13813113 | 0.79 | AAK1 (0.41) | KDM4EALDH1A1USP2CYP1A2GLA | |
| SCHEMBL14721223 | 0.78 | DRD2 (0.39) | ENPP2ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL29951580 | 0.78 | DRD2 (0.44) | ENPP2ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL16564308 | 0.78 | DRD2 (0.44) | ENPP2ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL29821479 | 0.77 | ALDH1A1 (0.56) | ENPP2KDM4EALDH1A1USP2IMPDH2 | |
| SCHEMBL3274361 | 0.77 | ALDH1A1 (0.56) | ENPP2KDM4EALDH1A1USP2IMPDH2 | |
| SCHEMBL15156401 | 0.76 | ENPP2 (0.52) | ENPP2 | |
| SCHEMBL3589010 | 0.75 | XDH (0.47) | ENPP2ALDH1A1XDH | |
| SCHEMBL21751397 | 0.75 | TTR (0.38) | ENPP2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9597310-B2 | Indanyloxydihydrobenzofuranylacetic acids | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-03-21 | — | — | US | disclosed |
| US-9597310-B2 | Indanyloxydihydrobenzofuranylacetic acids | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-03-21 | — | — | US | disclosed |
| US-9597310-B2 | Indanyloxydihydrobenzofuranylacetic acids | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-03-21 | — | — | US | disclosed |
| EP-2928886-B1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INT (DE) | 2016-11-02 | — | — | EP | disclosed |
| US-20160235706-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-18 | — | — | US | disclosed |
| US-20160235706-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-18 | — | — | US | disclosed |
| US-20160235706-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-18 | — | — | US | disclosed |
| EP-2928886-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | Boehringer Ingelheim International GmbH (DE) | 2015-10-14 | — | — | EP | disclosed |
| US-20140163025-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-12 | — | — | US | disclosed |
| US-20140163025-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-12 | — | — | US | disclosed |
| US-20140163025-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-12 | — | — | US | disclosed |
| WO-2014086712-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163025-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | GPR119, GPBAR1, GPR52 | ENPP2 342/4885KDM4E 3625/4885ALDH1A1 341/4885 |
| US-20160235706-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | GPR119, GPBAR1, GPR52 | ENPP2 342/4885KDM4E 3625/4885ALDH1A1 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.